Head-to-Head Comparison of [68 Ga]Ga-FAPI-46-PET/CT and [18F]F-FDG-PET/CT for Radiotherapy Planning in Head and Neck Cancer
Introduction In head and neck cancers (HNCs), fibroblast activation protein (FAP) is expressed by cancer-associated fibroblasts (CAFs) in the tumor microenvironment. Preliminary evidence suggests that detection and staging is feasible with positron emission tomography (PET/CT) imaging using [ 68...
Gespeichert in:
| Veröffentlicht in: | Molecular imaging and biology 2022-12, Vol.24 (6), p.986-994 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 994 |
|---|---|
| container_issue | 6 |
| container_start_page | 986 |
| container_title | Molecular imaging and biology |
| container_volume | 24 |
| creator | Wegen, Simone van Heek, Lutz Linde, Philipp Claus, Karina Akuamoa-Boateng, Dennis Baues, Christian Sharma, Shachi Jenny Schomäcker, Klaus Fischer, Thomas Roth, Katrin Sabine Klußmann, Jens Peter Marnitz, Simone Drzezga, Alexander Kobe, Carsten |
| description |
Introduction
In head and neck cancers (HNCs), fibroblast activation protein (FAP) is expressed by cancer-associated fibroblasts (CAFs) in the tumor microenvironment. Preliminary evidence suggests that detection and staging is feasible with positron emission tomography (PET/CT) imaging using [
68
Ga]-radiolabeled inhibitors of FAP ([
68
Ga]Ga-FAPI-46) in HNCs. This study aims to compare [
68
Ga]Ga-FAPI-46 PET/CT and [
18
F]-fluorodeoxy-
d
-glucose ([
18
F]F-FDG) PET/CT with a focus on improved target volume definition and radiotherapy planning in patients with HNC referred for chemoradiation.
Methods
A total of 15 patients with HNCs received both [
68
Ga]Ga-FAPI-46 PET/CT and [
18
F]F-FDG PET/CT with a thermoplastic mask, in addition to initial tumor staging by conventional imaging with contrast-enhanced CT and/or MRI. Mean intervals between FAPI/FDG and FAPI/conventional imaging were 4 ± 20 and 17 ± 18 days, respectively. Location and number of suspicious lesions revealed by the different procedures were recorded. Subsequently, expert-generated gross tumor volumes (GTVs) based on conventional imaging were compared to those based on [
18
F]F-FDG and [
68
Ga]Ga-FAPI-46 PET/CT to measure the impact on subsequent radiation planning.
Results
All patients had focal FAPI uptake above background in tumor lesions. Compared to FDG, tumor uptake (median SUVmax 10.2 vs. 7.3,
p
= 0.008) and tumor-to-background ratios were significantly higher with FAPI than with FDG (SUVmean liver: 9.3 vs. 3.2,
p
|
| doi_str_mv | 10.1007/s11307-022-01749-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9681697</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2739128994</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-b8abb70acb1cd380ca909b3c9769f49b2d1f52a4d8b9f96ec9764a01870f64ec3</originalsourceid><addsrcrecordid>eNp9kd1qFEEQhRtRTIy-gBfS4HWb_tv-uRHCmNkEgi6yXoXQ1PT0bCbudq_ds0LAh_FZfDJnsknUG6-qqHPqq4KD0GtG3zFK9XFhTFBNKOeEMi0t0U_QITOKEk4pfzr2M6EIU4IfoBel3NDRxbh4jg7ETGsmmD5EP84CtGRIZKq4Spst5L6kiFOHL5X59XMOV3Mg9cninEhFFqfL42qJIbb4kpn6qib1h_nDtEsZf4a2T8N1yLC9xYs1xNjHFe4jvuNPex-D_4oriD7kl-hZB-sSXt3XI_SlPl1WZ-Ti0_y8OrkgXmo5kMZA02gKvmG-FYZ6sNQ2wlutbCdtw1vWzTjI1jS2sypMggTKjKadksGLI_R-z93umk1ofYhDhrXb5n4D-dYl6N2_Suyv3Sp9d1YZpqweAW_vATl924UyuJu0y3H82XEtLOPGWjm6-N7lcyolh-7xAqNuSsztE3NjYu4uMTeh3_z92-PKQ0SjQewNZZTiKuQ_t_-D_Q2en59G</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2739128994</pqid></control><display><type>article</type><title>Head-to-Head Comparison of [68 Ga]Ga-FAPI-46-PET/CT and [18F]F-FDG-PET/CT for Radiotherapy Planning in Head and Neck Cancer</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Wegen, Simone ; van Heek, Lutz ; Linde, Philipp ; Claus, Karina ; Akuamoa-Boateng, Dennis ; Baues, Christian ; Sharma, Shachi Jenny ; Schomäcker, Klaus ; Fischer, Thomas ; Roth, Katrin Sabine ; Klußmann, Jens Peter ; Marnitz, Simone ; Drzezga, Alexander ; Kobe, Carsten</creator><creatorcontrib>Wegen, Simone ; van Heek, Lutz ; Linde, Philipp ; Claus, Karina ; Akuamoa-Boateng, Dennis ; Baues, Christian ; Sharma, Shachi Jenny ; Schomäcker, Klaus ; Fischer, Thomas ; Roth, Katrin Sabine ; Klußmann, Jens Peter ; Marnitz, Simone ; Drzezga, Alexander ; Kobe, Carsten</creatorcontrib><description>
Introduction
In head and neck cancers (HNCs), fibroblast activation protein (FAP) is expressed by cancer-associated fibroblasts (CAFs) in the tumor microenvironment. Preliminary evidence suggests that detection and staging is feasible with positron emission tomography (PET/CT) imaging using [
68
Ga]-radiolabeled inhibitors of FAP ([
68
Ga]Ga-FAPI-46) in HNCs. This study aims to compare [
68
Ga]Ga-FAPI-46 PET/CT and [
18
F]-fluorodeoxy-
d
-glucose ([
18
F]F-FDG) PET/CT with a focus on improved target volume definition and radiotherapy planning in patients with HNC referred for chemoradiation.
Methods
A total of 15 patients with HNCs received both [
68
Ga]Ga-FAPI-46 PET/CT and [
18
F]F-FDG PET/CT with a thermoplastic mask, in addition to initial tumor staging by conventional imaging with contrast-enhanced CT and/or MRI. Mean intervals between FAPI/FDG and FAPI/conventional imaging were 4 ± 20 and 17 ± 18 days, respectively. Location and number of suspicious lesions revealed by the different procedures were recorded. Subsequently, expert-generated gross tumor volumes (GTVs) based on conventional imaging were compared to those based on [
18
F]F-FDG and [
68
Ga]Ga-FAPI-46 PET/CT to measure the impact on subsequent radiation planning.
Results
All patients had focal FAPI uptake above background in tumor lesions. Compared to FDG, tumor uptake (median SUVmax 10.2 vs. 7.3,
p
= 0.008) and tumor-to-background ratios were significantly higher with FAPI than with FDG (SUVmean liver: 9.3 vs. 3.2,
p
< 0.001; SUVmean bloodpool: 6.9 vs. 4.0,
p
< 0.001). A total of 49 lesions were recorded. Of these, 40 (82%) were FDG
+
and 41 (84%) were FAP
+
. There were 5 (10%) FAP
+
/FDG
−
lesions and 4 (8%) FAP
−
/FDG
+
lesions. Volumetrically, a significant difference was found between the GTVs (median 57.9 ml in the FAPI-GTV, 42.5 ml in the FDG-GTV, compared to 39.2 ml in the conventional-GTV). Disease stage identified by FAPI PET/CT was mostly concordant with FDG PET/CT. Compared to conventional imaging, five patients (33%) were upstaged following imaging with FAPI and FDG PET/CT.
Conclusion
We demonstrate that [
68
Ga]Ga-FAPI-46 -PET/CT is useful for detecting tumor lesions in patients with HNCs. There is now a need for prospective randomized studies to confirm the role of [
68
Ga]Ga-FAPI-46 PET/CT in relation to [
18
F]F-FDG PET/CT in HNCs and to evaluate its impact on clinical outcome.</description><identifier>ISSN: 1536-1632</identifier><identifier>EISSN: 1860-2002</identifier><identifier>DOI: 10.1007/s11307-022-01749-7</identifier><identifier>PMID: 35771317</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Cancer ; Chemoradiotherapy ; Computed tomography ; Fibroblast activation protein ; Fibroblasts ; Fluorine isotopes ; Fluorodeoxyglucose F18 ; Gallium Radioisotopes ; Glucose ; Head & neck cancer ; Head and Neck Neoplasms - diagnostic imaging ; Head and Neck Neoplasms - radiotherapy ; Humans ; Imaging ; Lesions ; Medical imaging ; Medicine ; Medicine & Public Health ; Patients ; Positron emission ; Positron emission tomography ; Positron Emission Tomography Computed Tomography - methods ; Prospective Studies ; Quinolines ; Radiation ; Radiation therapy ; Radiology ; Radiopharmaceuticals ; Research Article ; Tumor Microenvironment ; Tumors</subject><ispartof>Molecular imaging and biology, 2022-12, Vol.24 (6), p.986-994</ispartof><rights>The Author(s) 2022</rights><rights>2022. The Author(s).</rights><rights>The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-b8abb70acb1cd380ca909b3c9769f49b2d1f52a4d8b9f96ec9764a01870f64ec3</citedby><cites>FETCH-LOGICAL-c474t-b8abb70acb1cd380ca909b3c9769f49b2d1f52a4d8b9f96ec9764a01870f64ec3</cites><orcidid>0000-0002-0361-728X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11307-022-01749-7$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11307-022-01749-7$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35771317$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wegen, Simone</creatorcontrib><creatorcontrib>van Heek, Lutz</creatorcontrib><creatorcontrib>Linde, Philipp</creatorcontrib><creatorcontrib>Claus, Karina</creatorcontrib><creatorcontrib>Akuamoa-Boateng, Dennis</creatorcontrib><creatorcontrib>Baues, Christian</creatorcontrib><creatorcontrib>Sharma, Shachi Jenny</creatorcontrib><creatorcontrib>Schomäcker, Klaus</creatorcontrib><creatorcontrib>Fischer, Thomas</creatorcontrib><creatorcontrib>Roth, Katrin Sabine</creatorcontrib><creatorcontrib>Klußmann, Jens Peter</creatorcontrib><creatorcontrib>Marnitz, Simone</creatorcontrib><creatorcontrib>Drzezga, Alexander</creatorcontrib><creatorcontrib>Kobe, Carsten</creatorcontrib><title>Head-to-Head Comparison of [68 Ga]Ga-FAPI-46-PET/CT and [18F]F-FDG-PET/CT for Radiotherapy Planning in Head and Neck Cancer</title><title>Molecular imaging and biology</title><addtitle>Mol Imaging Biol</addtitle><addtitle>Mol Imaging Biol</addtitle><description>
Introduction
In head and neck cancers (HNCs), fibroblast activation protein (FAP) is expressed by cancer-associated fibroblasts (CAFs) in the tumor microenvironment. Preliminary evidence suggests that detection and staging is feasible with positron emission tomography (PET/CT) imaging using [
68
Ga]-radiolabeled inhibitors of FAP ([
68
Ga]Ga-FAPI-46) in HNCs. This study aims to compare [
68
Ga]Ga-FAPI-46 PET/CT and [
18
F]-fluorodeoxy-
d
-glucose ([
18
F]F-FDG) PET/CT with a focus on improved target volume definition and radiotherapy planning in patients with HNC referred for chemoradiation.
Methods
A total of 15 patients with HNCs received both [
68
Ga]Ga-FAPI-46 PET/CT and [
18
F]F-FDG PET/CT with a thermoplastic mask, in addition to initial tumor staging by conventional imaging with contrast-enhanced CT and/or MRI. Mean intervals between FAPI/FDG and FAPI/conventional imaging were 4 ± 20 and 17 ± 18 days, respectively. Location and number of suspicious lesions revealed by the different procedures were recorded. Subsequently, expert-generated gross tumor volumes (GTVs) based on conventional imaging were compared to those based on [
18
F]F-FDG and [
68
Ga]Ga-FAPI-46 PET/CT to measure the impact on subsequent radiation planning.
Results
All patients had focal FAPI uptake above background in tumor lesions. Compared to FDG, tumor uptake (median SUVmax 10.2 vs. 7.3,
p
= 0.008) and tumor-to-background ratios were significantly higher with FAPI than with FDG (SUVmean liver: 9.3 vs. 3.2,
p
< 0.001; SUVmean bloodpool: 6.9 vs. 4.0,
p
< 0.001). A total of 49 lesions were recorded. Of these, 40 (82%) were FDG
+
and 41 (84%) were FAP
+
. There were 5 (10%) FAP
+
/FDG
−
lesions and 4 (8%) FAP
−
/FDG
+
lesions. Volumetrically, a significant difference was found between the GTVs (median 57.9 ml in the FAPI-GTV, 42.5 ml in the FDG-GTV, compared to 39.2 ml in the conventional-GTV). Disease stage identified by FAPI PET/CT was mostly concordant with FDG PET/CT. Compared to conventional imaging, five patients (33%) were upstaged following imaging with FAPI and FDG PET/CT.
Conclusion
We demonstrate that [
68
Ga]Ga-FAPI-46 -PET/CT is useful for detecting tumor lesions in patients with HNCs. There is now a need for prospective randomized studies to confirm the role of [
68
Ga]Ga-FAPI-46 PET/CT in relation to [
18
F]F-FDG PET/CT in HNCs and to evaluate its impact on clinical outcome.</description><subject>Cancer</subject><subject>Chemoradiotherapy</subject><subject>Computed tomography</subject><subject>Fibroblast activation protein</subject><subject>Fibroblasts</subject><subject>Fluorine isotopes</subject><subject>Fluorodeoxyglucose F18</subject><subject>Gallium Radioisotopes</subject><subject>Glucose</subject><subject>Head & neck cancer</subject><subject>Head and Neck Neoplasms - diagnostic imaging</subject><subject>Head and Neck Neoplasms - radiotherapy</subject><subject>Humans</subject><subject>Imaging</subject><subject>Lesions</subject><subject>Medical imaging</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Patients</subject><subject>Positron emission</subject><subject>Positron emission tomography</subject><subject>Positron Emission Tomography Computed Tomography - methods</subject><subject>Prospective Studies</subject><subject>Quinolines</subject><subject>Radiation</subject><subject>Radiation therapy</subject><subject>Radiology</subject><subject>Radiopharmaceuticals</subject><subject>Research Article</subject><subject>Tumor Microenvironment</subject><subject>Tumors</subject><issn>1536-1632</issn><issn>1860-2002</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><recordid>eNp9kd1qFEEQhRtRTIy-gBfS4HWb_tv-uRHCmNkEgi6yXoXQ1PT0bCbudq_ds0LAh_FZfDJnsknUG6-qqHPqq4KD0GtG3zFK9XFhTFBNKOeEMi0t0U_QITOKEk4pfzr2M6EIU4IfoBel3NDRxbh4jg7ETGsmmD5EP84CtGRIZKq4Spst5L6kiFOHL5X59XMOV3Mg9cninEhFFqfL42qJIbb4kpn6qib1h_nDtEsZf4a2T8N1yLC9xYs1xNjHFe4jvuNPex-D_4oriD7kl-hZB-sSXt3XI_SlPl1WZ-Ti0_y8OrkgXmo5kMZA02gKvmG-FYZ6sNQ2wlutbCdtw1vWzTjI1jS2sypMggTKjKadksGLI_R-z93umk1ofYhDhrXb5n4D-dYl6N2_Suyv3Sp9d1YZpqweAW_vATl924UyuJu0y3H82XEtLOPGWjm6-N7lcyolh-7xAqNuSsztE3NjYu4uMTeh3_z92-PKQ0SjQewNZZTiKuQ_t_-D_Q2en59G</recordid><startdate>20221201</startdate><enddate>20221201</enddate><creator>Wegen, Simone</creator><creator>van Heek, Lutz</creator><creator>Linde, Philipp</creator><creator>Claus, Karina</creator><creator>Akuamoa-Boateng, Dennis</creator><creator>Baues, Christian</creator><creator>Sharma, Shachi Jenny</creator><creator>Schomäcker, Klaus</creator><creator>Fischer, Thomas</creator><creator>Roth, Katrin Sabine</creator><creator>Klußmann, Jens Peter</creator><creator>Marnitz, Simone</creator><creator>Drzezga, Alexander</creator><creator>Kobe, Carsten</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>P64</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-0361-728X</orcidid></search><sort><creationdate>20221201</creationdate><title>Head-to-Head Comparison of [68 Ga]Ga-FAPI-46-PET/CT and [18F]F-FDG-PET/CT for Radiotherapy Planning in Head and Neck Cancer</title><author>Wegen, Simone ; van Heek, Lutz ; Linde, Philipp ; Claus, Karina ; Akuamoa-Boateng, Dennis ; Baues, Christian ; Sharma, Shachi Jenny ; Schomäcker, Klaus ; Fischer, Thomas ; Roth, Katrin Sabine ; Klußmann, Jens Peter ; Marnitz, Simone ; Drzezga, Alexander ; Kobe, Carsten</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-b8abb70acb1cd380ca909b3c9769f49b2d1f52a4d8b9f96ec9764a01870f64ec3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Cancer</topic><topic>Chemoradiotherapy</topic><topic>Computed tomography</topic><topic>Fibroblast activation protein</topic><topic>Fibroblasts</topic><topic>Fluorine isotopes</topic><topic>Fluorodeoxyglucose F18</topic><topic>Gallium Radioisotopes</topic><topic>Glucose</topic><topic>Head & neck cancer</topic><topic>Head and Neck Neoplasms - diagnostic imaging</topic><topic>Head and Neck Neoplasms - radiotherapy</topic><topic>Humans</topic><topic>Imaging</topic><topic>Lesions</topic><topic>Medical imaging</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Patients</topic><topic>Positron emission</topic><topic>Positron emission tomography</topic><topic>Positron Emission Tomography Computed Tomography - methods</topic><topic>Prospective Studies</topic><topic>Quinolines</topic><topic>Radiation</topic><topic>Radiation therapy</topic><topic>Radiology</topic><topic>Radiopharmaceuticals</topic><topic>Research Article</topic><topic>Tumor Microenvironment</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wegen, Simone</creatorcontrib><creatorcontrib>van Heek, Lutz</creatorcontrib><creatorcontrib>Linde, Philipp</creatorcontrib><creatorcontrib>Claus, Karina</creatorcontrib><creatorcontrib>Akuamoa-Boateng, Dennis</creatorcontrib><creatorcontrib>Baues, Christian</creatorcontrib><creatorcontrib>Sharma, Shachi Jenny</creatorcontrib><creatorcontrib>Schomäcker, Klaus</creatorcontrib><creatorcontrib>Fischer, Thomas</creatorcontrib><creatorcontrib>Roth, Katrin Sabine</creatorcontrib><creatorcontrib>Klußmann, Jens Peter</creatorcontrib><creatorcontrib>Marnitz, Simone</creatorcontrib><creatorcontrib>Drzezga, Alexander</creatorcontrib><creatorcontrib>Kobe, Carsten</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Molecular imaging and biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wegen, Simone</au><au>van Heek, Lutz</au><au>Linde, Philipp</au><au>Claus, Karina</au><au>Akuamoa-Boateng, Dennis</au><au>Baues, Christian</au><au>Sharma, Shachi Jenny</au><au>Schomäcker, Klaus</au><au>Fischer, Thomas</au><au>Roth, Katrin Sabine</au><au>Klußmann, Jens Peter</au><au>Marnitz, Simone</au><au>Drzezga, Alexander</au><au>Kobe, Carsten</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Head-to-Head Comparison of [68 Ga]Ga-FAPI-46-PET/CT and [18F]F-FDG-PET/CT for Radiotherapy Planning in Head and Neck Cancer</atitle><jtitle>Molecular imaging and biology</jtitle><stitle>Mol Imaging Biol</stitle><addtitle>Mol Imaging Biol</addtitle><date>2022-12-01</date><risdate>2022</risdate><volume>24</volume><issue>6</issue><spage>986</spage><epage>994</epage><pages>986-994</pages><issn>1536-1632</issn><eissn>1860-2002</eissn><abstract>
Introduction
In head and neck cancers (HNCs), fibroblast activation protein (FAP) is expressed by cancer-associated fibroblasts (CAFs) in the tumor microenvironment. Preliminary evidence suggests that detection and staging is feasible with positron emission tomography (PET/CT) imaging using [
68
Ga]-radiolabeled inhibitors of FAP ([
68
Ga]Ga-FAPI-46) in HNCs. This study aims to compare [
68
Ga]Ga-FAPI-46 PET/CT and [
18
F]-fluorodeoxy-
d
-glucose ([
18
F]F-FDG) PET/CT with a focus on improved target volume definition and radiotherapy planning in patients with HNC referred for chemoradiation.
Methods
A total of 15 patients with HNCs received both [
68
Ga]Ga-FAPI-46 PET/CT and [
18
F]F-FDG PET/CT with a thermoplastic mask, in addition to initial tumor staging by conventional imaging with contrast-enhanced CT and/or MRI. Mean intervals between FAPI/FDG and FAPI/conventional imaging were 4 ± 20 and 17 ± 18 days, respectively. Location and number of suspicious lesions revealed by the different procedures were recorded. Subsequently, expert-generated gross tumor volumes (GTVs) based on conventional imaging were compared to those based on [
18
F]F-FDG and [
68
Ga]Ga-FAPI-46 PET/CT to measure the impact on subsequent radiation planning.
Results
All patients had focal FAPI uptake above background in tumor lesions. Compared to FDG, tumor uptake (median SUVmax 10.2 vs. 7.3,
p
= 0.008) and tumor-to-background ratios were significantly higher with FAPI than with FDG (SUVmean liver: 9.3 vs. 3.2,
p
< 0.001; SUVmean bloodpool: 6.9 vs. 4.0,
p
< 0.001). A total of 49 lesions were recorded. Of these, 40 (82%) were FDG
+
and 41 (84%) were FAP
+
. There were 5 (10%) FAP
+
/FDG
−
lesions and 4 (8%) FAP
−
/FDG
+
lesions. Volumetrically, a significant difference was found between the GTVs (median 57.9 ml in the FAPI-GTV, 42.5 ml in the FDG-GTV, compared to 39.2 ml in the conventional-GTV). Disease stage identified by FAPI PET/CT was mostly concordant with FDG PET/CT. Compared to conventional imaging, five patients (33%) were upstaged following imaging with FAPI and FDG PET/CT.
Conclusion
We demonstrate that [
68
Ga]Ga-FAPI-46 -PET/CT is useful for detecting tumor lesions in patients with HNCs. There is now a need for prospective randomized studies to confirm the role of [
68
Ga]Ga-FAPI-46 PET/CT in relation to [
18
F]F-FDG PET/CT in HNCs and to evaluate its impact on clinical outcome.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>35771317</pmid><doi>10.1007/s11307-022-01749-7</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-0361-728X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1536-1632 |
| ispartof | Molecular imaging and biology, 2022-12, Vol.24 (6), p.986-994 |
| issn | 1536-1632 1860-2002 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9681697 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Cancer Chemoradiotherapy Computed tomography Fibroblast activation protein Fibroblasts Fluorine isotopes Fluorodeoxyglucose F18 Gallium Radioisotopes Glucose Head & neck cancer Head and Neck Neoplasms - diagnostic imaging Head and Neck Neoplasms - radiotherapy Humans Imaging Lesions Medical imaging Medicine Medicine & Public Health Patients Positron emission Positron emission tomography Positron Emission Tomography Computed Tomography - methods Prospective Studies Quinolines Radiation Radiation therapy Radiology Radiopharmaceuticals Research Article Tumor Microenvironment Tumors |
| title | Head-to-Head Comparison of [68 Ga]Ga-FAPI-46-PET/CT and [18F]F-FDG-PET/CT for Radiotherapy Planning in Head and Neck Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T20%3A21%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Head-to-Head%20Comparison%20of%20%5B68%C2%A0Ga%5DGa-FAPI-46-PET/CT%20and%20%5B18F%5DF-FDG-PET/CT%20for%20Radiotherapy%20Planning%20in%20Head%20and%20Neck%20Cancer&rft.jtitle=Molecular%20imaging%20and%20biology&rft.au=Wegen,%20Simone&rft.date=2022-12-01&rft.volume=24&rft.issue=6&rft.spage=986&rft.epage=994&rft.pages=986-994&rft.issn=1536-1632&rft.eissn=1860-2002&rft_id=info:doi/10.1007/s11307-022-01749-7&rft_dat=%3Cproquest_pubme%3E2739128994%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2739128994&rft_id=info:pmid/35771317&rfr_iscdi=true |